Delivery Order SPE2DB22D3501-SPE2DB24FWP25

Award Date 8/8/24
Potential Completion Date 8/9/24
Potential Value $6.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation's Corporate Office division. The $1,741.62 firm fixed price delivery order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a pharmaceutical product. This award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 through December 2025, which enables the DLA to procure a comprehensive range of medical commodities from...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $25,133.91 firm fixed-price delivery order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a diabetes medication. The contract has an ultimate completion date of May 2, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,382.18 Firm Fixed Price Delivery Order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for diabetes management. The contract has an Ultimate Completion Date of October 22, 2024. The award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,879.98 firm fixed-price delivery order is for OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a diabetes medication. The contract has an ultimate completion date of March 14, 2025. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical,...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,326.72 firm-fixed-price delivery order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a pharmaceutical product. This award is not associated with a set-aside designation. The contract has an ultimate completion date of July 23, 2024 and is part of AmerisourceBergen's broader Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $17,880.52 firm fixed-price delivery order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a medication used for diabetes management. The contract has an ultimate completion date of May 14, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,879.98 firm fixed-price delivery order contract is for OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, with a period of performance through February 12, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $59,377.14, is for the delivery of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order with a completion date of January 15, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,991.18 firm fixed-price delivery order is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, with an ultimate completion date of October 11, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves...
This is a $2,474.37 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the provision of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a pharmaceutical product, to support military healthcare programs. The award has an ultimate completion date of December 11, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB24FWP25
    Delivery Order

This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office division. The $6,852.76 firm-fixed-price contract is for the supply of OZEMPIC 0.25-0.5 MG/DOSE PEN 3ML, a pharmaceutical product. The award is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation and is scheduled for completion by August 9, 2024.

Generated 11/7/24, 9:11 AM